Chronic treatment with bark infusion from Croton cajucara lowers plasma triglyceride levels in genetic hyperlipidemic mice.

Aqueous infusion and preparations containing dehydrocrotonin (DHC) and essential oil from Croton cajucara bark were tested for plasma lipid-lowering effects in genetically modified hyperlipidemic mice. Two mouse models were tested: 1) primary hypercholesterolemia resulting from the LDL-receptor gene knockout, and 2) combined hyperlipidemia resulting from crosses of LDL-receptor knockout mice with transgenic mice overexpressing apolipo protein (apo) CIII and cholesteryl ester-transfer protein. Mice treated with bark infusion, DHC, essential oil, or placebos for 25 days showed no signals of toxicity as judged by biochemical tests for liver and kidney functions. The bark infusion reduced triglyceride plasma levels by 40%, while essential oil and DHC had no significant effects on plasma lipid levels. The bark infusion treatment promoted a redistribution of cholesterol among the lipoprotein fractions in combined hyperlipidemic mice. There was a marked reduction in the VLDL fraction and an increase in the HDL fraction, in such a way that the (VLDL + LDL)/HDL ratio was reduced by half. The bark infusion treatment did not modify cholesterol distribution in hypercholesterolemic mice. In conclusion, C. cajucara bark infusion reduced plasma triglycerides levels and promoted a redistribution of cholesterol among lipoproteins in genetically combined hyperlipidemic mice. These changes modify risk factors for the development of atherosclerotic diseases.

[1]  D. Mangelsdorf,et al.  A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR , 2002, Science.

[2]  A. Brito,et al.  Effect of essential oil obtained from Croton cajucara Benth. on gastric ulcer healing and protective factors of the gastric mucosa. , 2002, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[3]  F. Santos,et al.  Blood glucose‐ and triglyceride‐lowering effect of trans‐dehydrocrotonin, a diterpene from Croton cajucara Benth., in rats , 2001, Diabetes, obesity & metabolism.

[4]  F. Santos,et al.  Effect of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental hypertriglyceridaemia and hypercholesterolaemia induced by Triton WR 1339 (tyloxapol) in mice. , 2001, Planta medica.

[5]  Joseph L. Goldstein,et al.  The Cholesterol Quartet , 2001, Science.

[6]  A. Boschero,et al.  Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice. , 2001, Metabolism: clinical and experimental.

[7]  Â. Pinto,et al.  The lipid‐lowering effect of trans‐dehydrocrotonin, a clerodane diterpene from Croton cajucara Benth. in mice fed on high‐fat diet , 2001, The Journal of pharmacy and pharmacology.

[8]  M. Malloy,et al.  A risk factor for atherosclerosis: triglyceride-rich lipoproteins. , 2001, Advances in internal medicine.

[9]  E. D. de Faria,et al.  Plasma lipases and lipid transfer proteins increase phospholipid but not free cholesterol transfer from lipid emulsion to high density lipoproteins. , 2001, BMC Biochemistry.

[10]  O. Færgeman.  Hypertriglyceridemia and the fibrate trials. , 2000 .

[11]  M. Miller,et al.  Current perspectives on the management of hypertriglyceridemia. , 2000, American heart journal.

[12]  Â. Pinto,et al.  Ethnopharmacology, phytochemistry and pharmacology: a successful combination in the study of Croton cajucara. , 2000, Journal of ethnopharmacology.

[13]  T. Ng,et al.  Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities. , 1999, Life sciences.

[14]  J. Dallongeville,et al.  Pinus pinaster oil affects lipoprotein metabolism in apolipoprotein E-deficient mice. , 1999, The Journal of nutrition.

[15]  W. Craig.  Health-promoting properties of common herbs. , 1999, The American journal of clinical nutrition.

[16]  Â. Pinto,et al.  Terpenoids from Croton cajucara , 1998 .

[17]  J. Rodríguez,et al.  Antiulcerogenic activity of trans-dehydrocrotonin from Croton cajucara. , 1998, Planta medica.

[18]  A. Tall,et al.  A Mouse Model with Features of Familial Combined Hyperlipidemia , 1997, Science.

[19]  G. Viana,et al.  Effects of Croton cajucara Extract on Serum Lipids of Rats Fed A High Fat Diet , 1996 .

[20]  J. Breslow,et al.  Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice. , 1996, Journal of lipid research.

[21]  J. Breslow.  Mouse Models of Atherosclerosis , 1996, Science.

[22]  H. Oliveira,et al.  'In vitro' cholesteryl ester bidirectional flow between high-density lipoproteins and triglyceride-rich emulsions: effects of particle concentration and composition, cholesteryl ester transfer activity and oleic acid. , 1996, Journal of biochemical and biophysical methods.

[23]  A. Tall.  Plasma lipid transfer proteins. , 1995, Annual Review of Biochemistry.

[24]  E. Rubin,et al.  The mouse as a model for human cardiovascular disease and hyperlipidemia. , 1994, Current opinion in lipidology.

[25]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[26]  J. Breslow,et al.  Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3' to the gene in the promoter of the adjacent convergently transcribed apoC-III gene. , 1993, Journal of lipid research.

[27]  Henry N. Ginsberg,et al.  Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. , 1992, The Journal of clinical investigation.

[28]  D. Severson,et al.  Regulation of the synthesis, processing and translocation of lipoprotein lipase. , 1992, The Biochemical journal.

[29]  A. Tall,et al.  Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. , 1992, The Journal of clinical investigation.

[30]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[31]  M. Brown,et al.  The low-density lipoprotein pathway and its relation to atherosclerosis. , 1977, Annual review of biochemistry.

[32]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[33]  W. Brown,et al.  Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. , 1972, Biochemical and biophysical research communications.